Urine test may detect kidney cancer early
the ONA take:
According to a recent study published in JAMA Oncology, researchers at Washington University School of Medicine in St. Louis, Missouri, have developed a noninvasive urine test that screens for kidney cancer.
For the study of the screening method, researchers analyzed urine samples from 720 patients were about to undergo an abdominal CT scan for reasons other than suspicion of kidney cancer, 80 healthy people, and 19 patients previously diagnosed with cancer. The test measured levels of two proteins biomarkers in the urine.
Results showed that none of the 80 healthy people had increased levels of either biomarker and all of the 19 patients with kidney cancer had elevated levels of both. In addition, three of the 720 patients who underwent an abdominal CT scan had increased levels of both proteins; two were confirmed to have kidney cancer.
Ultimately, the protein biomarkers were over 95% accurate in identifying early-stage kidney cancer and the test did not result in any false-positive caused by non-cancerous kidney disease.
Researchers developed a noninvasive urine test that screens for kidney cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|